CN114569679A - 一种降血糖中药组合物及其应用 - Google Patents
一种降血糖中药组合物及其应用 Download PDFInfo
- Publication number
- CN114569679A CN114569679A CN202210285775.2A CN202210285775A CN114569679A CN 114569679 A CN114569679 A CN 114569679A CN 202210285775 A CN202210285775 A CN 202210285775A CN 114569679 A CN114569679 A CN 114569679A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 210000004369 blood Anatomy 0.000 title claims abstract description 60
- 239000008280 blood Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 235000000346 sugar Nutrition 0.000 title claims abstract description 36
- 230000001603 reducing effect Effects 0.000 title claims abstract description 25
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 240000000249 Morus alba Species 0.000 claims abstract description 11
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 11
- 240000008042 Zea mays Species 0.000 claims abstract description 11
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 10
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 10
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 9
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 9
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 9
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 9
- 235000005822 corn Nutrition 0.000 claims abstract description 9
- 230000001737 promoting effect Effects 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 8
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 238000010791 quenching Methods 0.000 claims abstract description 7
- 230000035922 thirst Effects 0.000 claims abstract description 7
- 210000001124 body fluid Anatomy 0.000 claims abstract description 6
- 239000010839 body fluid Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 12
- 150000004676 glycans Chemical class 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 8
- 241000234435 Lilium Species 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000011837 pasties Nutrition 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 35
- 230000001976 improved effect Effects 0.000 abstract description 6
- 230000000171 quenching effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 91
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 33
- 239000008103 glucose Substances 0.000 description 33
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 206010012601 diabetes mellitus Diseases 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 20
- 206010022489 Insulin Resistance Diseases 0.000 description 15
- 238000001647 drug administration Methods 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 11
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 10
- 102000013275 Somatomedins Human genes 0.000 description 10
- 235000020828 fasting Nutrition 0.000 description 10
- 230000036039 immunity Effects 0.000 description 9
- 108010075254 C-Peptide Proteins 0.000 description 8
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 8
- 210000000702 aorta abdominal Anatomy 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108091005995 glycated hemoglobin Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 3
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241000037831 Polygonatum sibiricum Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940089639 cornsilk Drugs 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000001231 zea mays silk Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 240000001549 Ipomoea eriocarpa Species 0.000 description 1
- 235000005146 Ipomoea eriocarpa Nutrition 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101500025617 Rattus norvegicus Transforming growth factor beta-1 Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- -1 homoisoflavone Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种降血糖中药组合物及其应用,涉及中药产品技术领域。本发明所述降血糖中药组合物包括如下重量份的成分:玉米须20~40份、葛根10~25份、黄精5~25份、桑叶5~20份、茯苓5~20份、山药5~10份和枸杞子5~10份。所述中药组合物中,各中药材之间存在协同作用,可以协同提升中药组合物的降血糖作用,并且还具有生津止渴的功效。
Description
技术领域
本发明涉及中药产品技术领域,尤其涉及一种降血糖中药组合物及其应用。
背景技术
随着生活水平的提高,居民饮食结构中高糖、高脂、高蛋白的摄入量逐步增加,导致糖尿病、高血脂等病症的发生率也随之增加。此外,研究发现,生活、工作压力导致的失眠、内分泌失调等也会影响血糖水平,使糖尿病等疾病的发病率增加。
目前有多种西药和中成药可以降血糖,但长期服用会产生一定的副作用,因此,亟需开发一款药食同源、对人体安全的降血糖中药组合物。
发明内容
本发明的目的在于克服上述现有技术的不足之处而提供一种对人体安全,并且具有良好的降血糖、生津止渴功效的中药组合物及其应用。
为实现上述目的,本发明所采取的技术方案为:
一种降血糖中药组合物,所述中药组合物包含如下重量份的成分:玉米须20~40份、葛根10~25份、黄精5~25份、桑叶5~20份、茯苓5~20份、山药5~10份和枸杞子5~10份。
玉米须能利尿、泄热、平肝、利胆等,不仅“入阳明胃经”,而且归肾、肝、胆经。功能利水消肿,清肝利胆。现代药理研究证实玉米须有利尿、利胆、降血压、降血糖、抗癌、止血等作用。(《玉米须的化学成分》)
葛根是葛在地底生长膨大的根,具有极高的食用和保健价值,并且在许多中医药典籍中均有记载。传统医药中,葛根常用于发热、腹泻、心绞痛等的辅助治疗。现代药理学研究证实,葛根具有多种生物活性作用,如雌激素样活性、抗炎、抗氧化反应、控制血压、降低血糖、减少癌症发生等作用。(《葛根功效活性及其在食品中的应用进展》)
黄精为百合科植物,以干燥根茎入药。黄精中能分离出许多类型的化合物,如皂苷、高异黄酮、多糖类等,具有良好的抗疲劳作用、抗衰老作用、免疫调节作用、降血糖活性作用、神经保护作用以及抗炎活性。(《黄精功能成分的研究进展》)
桑叶是一种药食两用植物资源,味苦、甘,性寒,归肺、肝经,具有疏风清热、清肝明目等功效。研究表明,桑叶中含有丰富的活性成分如黄酮、多糖和生物碱等,在抗高血压、抗凝血、降血糖、降脂、抗肿瘤转移等方面有重要利用价值。(《桑叶生物碱对氧化应激小鼠糖脂代谢异常及肝损伤的改善作用》)
茯苓是多孔菌科、茯苓属真菌。茯苓中富含多种化学成分,主要有三萜类、多糖类、甾醇类、挥发油类、蛋白质、氨基酸及微量元素等,其中三萜类和多糖类化合物为茯苓的主要活性成分。茯苓多糖具有多种药理作用,包括免疫调节、抗肿瘤、抗氧化、抗炎、抗抑郁等。(《茯苓多糖及其免疫调节功能研究进展》)
山药是传统药食同源药物,具有免疫增强、抗衰老、抗突变等作用。研究发现,山药多糖对糖尿病小鼠体重的恢复具有促进作用。(《山药多糖对糖尿病小鼠降血糖作用》)
枸杞子通常指茄科植物宁夏枸杞的干燥成熟的果实。枸杞味甘、性平,主要归肝、肾、肺经,具有滋补肝肾、益精明目以及润肺的功效。动物实验表明,将枸杞子提取物用于大鼠,能持续降低大鼠血糖,显著提高糖耐量,这与枸杞子中含有胍的衍生物相关。
本发明通过选用玉米须、葛根、黄精、桑叶、茯苓、山药和枸杞子配伍,显著提升了中药组合物的降血糖功效。
优选地,所述中药组合物包含如下重量份的成分:玉米须25~35份、葛根15~20份、黄精10~20份、桑叶8~15份、茯苓8~15份、山药5~10份和枸杞子5~10份。《神农本草经·序例》将中药材的配伍关系归纳为“有单行者,有相须者,有相使者,有相畏者,有相恶者,有相反者,有相杀者,凡此七情,合和视之”。有的可以相互增进原有的疗效,有的则会削弱和抵消原有的功效。本发明通过对上述七种中药材的用量配比进行选择,使得所述中药组合物既具有优良的降血糖作用,也具有良好的降血脂作用。
优选地,所述中药组合物还含有乌梅1~10份。乌梅具有敛肺、涩肠、生津、安蛔的功效。现代研究发现,乌梅中的苹果酸和枸橼酸与乌梅肉、乌梅炭的降糖作用密切相关;实验发现,黄芪乌梅提取颗粒能有效地降低胰岛素抵抗模型大鼠的血糖,此外,黄芪乌梅提取颗粒还能明显纠正胰岛素抵抗模型大鼠的血脂水平。本发明通过在上述中药组合物中添加乌梅,明显提升了该中药组合物的降血糖及降血脂作用。
进一步优选地,所述中药组合物中还含有百合1~10份。百合自古以来即为药食两用植物,具有镇啶、祛痰、抗病劳、耐缺氧、抗癌等多种功能,另外据报道百合中的多糖有降血糖等多种功能。本发明通过实验发现,添加百合可以进一步提升所述中药组合物的综合性能。
此外,本发明还公开了一种以上述中药组合物制备而成的中药浸膏,所述中药浸膏为浅棕色至黑褐色的膏状半流体,总黄酮含量≥0.25wt.%,粗多糖含量≥2.5wt.%。另外,本发明还提供了一种所述中药浸膏的制备方法,包括如下步骤:
(1)按中药材与水的重量比1:6~10添加水,微沸1~5h,过滤,得滤渣和滤液;
(2)将滤渣与水以1:5~9的重量比混合,重复上述步骤1~3次;
(3)将上述步骤获得的滤液混合,减压、浓缩,得到所述中药浸膏;所述中药浸膏中固形物的含量为35~55%(20℃,折光计法)。
采用上述方法可以高效地提取出中药材中的活性物质,并且该方法工艺简单,适于应用在工业生产中。
同时,本发明还公开了上述中药组合物在制备降血糖和/或降血脂和/或生津止渴的食品饮料和药品领域中的应用。当应用于制备药物时,可以在上述中药组合物的基础上添加药物领域可接受的辅料,药物的剂型可以为汤剂、散剂、丸剂、膏剂中的任意一种。当应用于制备饮品时,还可以添加其他成分来丰富饮品的口味。
相比于现有技术,本发明的有益效果为:
本发明通过选用玉米须、葛根、黄精、桑叶、茯苓、山药、枸杞子配伍,组成的中药组合物对于降低血糖、治疗2型糖尿病具有较高的功效。此外,通过对各成分的配比进行选择,极大地提升了所述中药组合物的降血脂的作用。另外,通过添加乌梅,进一步提升了所述中药组合物的降血糖、降血脂的功效,并且提供了生津止渴的功效;通过进一步添加百合,也显著提升了所述中药组合物的综合性能。
具体实施方式
为更好地说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。
实施例1~8
本发明所述降血糖中药组合物的实施例,实施例1~8的配方如表1所示。
表1(重量份)
项目 | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | 实施例7 | 实施例8 |
玉米须 | 30 | 25 | 35 | 20 | 40 | 30 | 30 | 30 |
葛根 | 20 | 18 | 15 | 25 | 10 | 20 | 20 | 20 |
黄精 | 18 | 20 | 10 | 25 | 5 | 18 | 18 | 18 |
桑叶 | 14 | 15 | 8 | 20 | 5 | 14 | 14 | 14 |
茯苓 | 10 | 15 | 8 | 5 | 20 | 10 | 10 | 10 |
山药 | 10 | 5 | 10 | 5 | 15 | 10 | 10 | 10 |
枸杞子 | 5 | 5 | 10 | 15 | 5 | 5 | 5 | 5 |
乌梅 | 5 | 5 | ||||||
百合 | 5 | 5 |
将实施例1~8制备成中药浸膏,制备方法如下:
(1)将各成分粉碎成100目的粉末,按粉末与水的重量比1:8添加水,微沸2h,过滤,得到滤渣和滤液;
(2)将滤渣与水以1:7的重量比混合,微沸2h,过滤,得到滤渣和滤液;
(3)将上述步骤获得的滤液混合,减压、浓缩至固形物的含量(20℃,折光计法)为50±1%,得到中药浸膏,所述中药浸膏为浅棕色至黑褐色的膏状半流体,总黄酮含量≥0.25wt.%,粗多糖含量≥2.5wt.%。
效果验证
以实施例1~8制备的中药浸膏(分别标记为样品1~8)对实验性2型糖尿病模型大鼠的影响来验证所述中药组合物的功效。委托广州中医药大学科技产业园有限公司进行实验验证。
1、实验材料
1.1供试品与对照品
供试品为样品1~8,对照品为消渴丸(广州白云山中一药业有限公司,规格:0.25g/丸×300丸/瓶)。
1.2实验试剂
胆固醇:广州晶欣生物科技有限公司,规格:1kg;
葡萄糖:天津市大茂化学试剂厂,规格:500g;
去氧胆酸钠:广东环凯微生物科技有限公司,规格:100g;
丙硫氧嘧啶片:上海朝晖药业有限公司,规格:50mg×100片/瓶;
吐温-80:广东广试试剂科技有限公司,规格:500mL;
丙二醇:广东广试试剂科技有限公司,规格:500mL;
柠檬酸:天津市福晨化学试剂厂,规格:500g;
柠檬酸三钠:天津市福晨化学试剂厂,规格:500g;
链脲佐菌素:SIGMA,规格:1g;
乌来糖:国药集团化学试剂有限公司,规格:500g;
血糖试纸:德国罗氏诊断有限公司,规格:活力型、50片/筒;
氯化钠注射液:广东利泰制药股份有限公司,规格:500mL/瓶;
大鼠胰岛素(INS)试剂盒:江苏酶免实业有限公司;
大鼠糖化血红蛋白(HbAlc)试剂盒:江苏酶免实业有限公司;
大鼠C肽(C-P)试剂盒:江苏酶免实业有限公司;
大鼠糖基化终末产物(AGEs)试剂盒:江苏酶免实业有限公司;
大鼠转化生长因子β1(TGF-β1)试剂盒:江苏酶免实业有限公司;
大鼠胰岛素样生长因子1(IGF-1)试剂盒:江苏酶免实业有限公司;
大鼠谷氨酸脱羟酶抗体(GADA)试剂盒:江苏酶免实业有限公司。
1.3实验仪器
电子天平:奥豪斯仪器(常州)有限公司,型号:AX2202ZH,感量:0.01g;
电子天平:常熟市双杰测试仪器厂,型号:J2000,感量:0.1g;
分析天平:奥豪斯仪器(常州)有限公司,型号:CP224C,感量:0.1mg;
血糖仪:德国罗氏诊断有限公司,型号:活力型;
数显恒温水浴箱:江苏金坛市荣华仪器制造有限公司,型号:HH-6;
自动高压灭菌锅:日本Hirayama公司,型号:HVE-50;
电热恒温鼓风干燥箱:上海佳胜实验设备有限公司,型号:9070B;
全自动生化分析仪:HITACHI公司,日立7080;
酶标仪:赛默飞世尔科技有限公司,型号:Multiskan FC。
1.4实验动物
SD大鼠,180-220g,雄性,SPF级,由南方医科大学实验动物中心提供。
1.5实验动物的适应性观察
适应性饲养过程:自接收之日起,所有动物进行适应性饲养观察,每天观察1次;观察内容包括:精神状态是否良好、行为活动是否正常、被毛是否光滑、有无便溏、眼睛有无异常、会阴部有无异常分泌物及溃烂、有无死亡。适应性饲养合格动物纳入正式试验。
1.6实验动物饲养管理及环境条件
实验动物饲养于安评中心实验动物室D区DS房,自由摄食、饮水。
试验期间,实验动物室温度20℃-25℃,相对湿度40%-70%(WS-1型温湿度记录仪记录),照明为12h/12h明暗交替。
2、剂量设计及分组
样品1~8的临床拟用剂量为每日108g浸膏,1g浸膏约为1.9g生药,本实验供试品设低、中、高3个剂量组,分别等效于临床拟用剂量的0.5、1、2倍。对样品1的3个剂量组分别进行测试,对样品2~8的中剂量组进行测试。每一组使用12只大鼠进行实验研究。
对大鼠进行实际测试时供试品低、中、高剂量分别为9.75g生药·kg-1、19.50g生药·kg-1、39.00g生药·kg-1。
阳性对照药消渴丸临床剂量为每日7.5g,大鼠等效剂量为0.78g/kg。阳性对照药使用剂量等效于临床剂量的1倍。
3、统计分析
所有数据均用“均值±标准差”表示,试验数据运用SPSS17.0统计分析软件进行统计分析,组间差异性比较采用单因素方差分析(One-Way ANOVA),以LSD检验进行各组间两两比较。P<0.05为差异有统计学意义。
4、实验方法
取SD大鼠,雄性,180g-220g。经适应性饲养后,合格大鼠随机分为正常对照组与造模组。大鼠饲喂普通饲料,造模组大鼠同时灌胃给予高脂乳剂8周,8周后禁食不禁水12h,造模大鼠一次性腹腔注射链脲佐菌素(STZ)溶液30mg·kg-1(STZ临用前用0.1mol·L-1柠檬酸-檬酸钠缓冲液配制成1%浓度,调pH值至4.21,操作均在冰浴中进行)建立2型糖尿病大鼠模型。正常对照组大鼠腹腔注射等剂量柠檬酸-柠檬酸钠缓冲液。注射STZ 1周后大鼠禁食12h,用刀片划破大鼠尾部,用血糖仪检测大鼠空腹血糖(FGB),FGB≥11.1mmol·L-1即为造模成功。造模成功的大鼠分为模型对照组、样品1低、中、高剂量组、样品2中剂量组、样品3中剂量组、样品4中剂量组、样品5中剂量组、样品6中剂量组、样品7中剂量组、样品8中剂量组、消渴丸组,每组12只。灌胃给药,每天1次,连续8周。
5、检测指标
5.1体重、饮水量
给药期间,每周对大鼠进行称重,记录每组大鼠24h平均饮水量。
5.2血糖检测
给药2、4、6、8、10周及末次给药后,大鼠禁食不禁水12h,用刀片划破大鼠尾部,血糖仪检测空腹血糖(GLU)。
5.3糖耐量检测
末次给药后,大鼠禁食12h,测定0h血糖值后,立即按2g/kg灌服葡萄糖溶液,并测定灌服葡萄糖后0.5、1、2h时血糖值(BG0.5,BG1、BG2)。采用近似梯形的计算公式计算曲线下面积(AUC)。
AUC=(BG0+BG0.5)×0.5÷2+(BG0.5+BG1)×0.5÷2+(BG1+BG2)×1÷2
5.4尿糖检测
末次给药后,大鼠放入代谢笼收集尿液,记录尿量,用多项尿液检测试纸条检测尿糖结果。
5.5血脂检测
末次给药后,大鼠麻醉,腹主动脉取血,全自动生化分析仪测定血清中总胆固醇(CHOL)和甘油三酯(TG)。
5.6胰岛素检测
同5.5腹主动脉取血,酶联免疫试剂盒测定胰岛素(INS),并计算胰岛素抵抗指数与胰岛素敏感性指数。
胰岛素抵抗指数(IR)=(空腹血糖×空腹胰岛素)/22.5
胰岛素敏感性指数(IAI)=Ln[1/(空腹血糖×空腹胰岛素)]
5.7糖化血红蛋白检测
同5.5腹主动脉取血,酶联免疫试剂盒测定糖化血红蛋白(HbAlc)。
5.8胰岛素样生长因子1检测
同5.5腹主动脉取血,酶联免疫试剂盒测定胰岛素样生长因子1(IGF-1)。
5.9谷氨酸脱羟酶抗体检测
同5.5腹主动脉取血,酶联免疫试剂盒测定谷氨酸脱羟酶抗体(GADA)。
5.10 C肽检测
同5.5腹主动脉取血,酶联免疫试剂盒测定C肽(C-P)。
5.11糖基化终末产物检测
同5.5腹主动脉取血,酶联免疫试剂盒测定糖基化终末产物(AGEs)。
5.12转化生长因子β1检测
同5.5腹主动脉取血,酶联免疫试剂盒测定转化生长因子β1(TGF-β1)。
6、实验结果
6.1对实验性2型糖尿病模型大鼠体重和饮水量的影响
与正常对照组比较,模型对照组大鼠的体重显著降低(P<0.01);与模型对照组比较,各给药组大鼠体重无明显变化(P>0.05)。结果见表2、3。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
项目 | 给药5周体重(g) | 给药6周体重(g) | 给药7周体重(g) | 给药8周体重(g) |
正常对照组 | 523.35±49.58 | 527.66±49.47 | 531.24±49.86 | 540.97±48.56 |
模型对照组 | 286.26±72.61<sup>△△</sup> | 268.27±83.71<sup>△△</sup> | 276.72±82.05<sup>△△</sup> | 259.88±84.23<sup>△△</sup> |
样品1低剂量组 | 289.85±54.88 | 284.87±58.32 | 276.99±58.12 | 280.28±66.08 |
样品1中剂量组 | 261.08±42.94 | 280.58±27.21 | 266.73±25.25 | 268.02±31.61 |
样品1高剂量组 | 278.03±33.85 | 273.67±37.84 | 283.76±35.32 | 283.78±30.11 |
样品2中剂量组 | 286.53±40.21 | 285.39±28.17 | 280.48±39.20 | 275.43±29.87 |
样品3中剂量组 | 281.47±32.22 | 276.43±33.52 | 278.64±32.67 | 272.89±28.70 |
样品4中剂量组 | 275.56±40.12 | 265.23±38.12 | 268.71±35.31 | 261.85±34.29 |
样品5中剂量组 | 273.18±39.28 | 275.36±39.24 | 265.88±34.26 | 258.49±36.12 |
样品6中剂量组 | 284.33±34.51 | 280.34±35.24 | 285.19±40.01 | 280.32±30.92 |
样品7中剂量组 | 283.92±30.29 | 281.25±32.29 | 284.40±32.88 | 279.48±28.37 |
样品8中剂量组 | 290.75±27.38 | 287.65±31.72 | 290.13±20.45 | 285.57±36.18 |
消渴丸组 | 263.34±45.71 | 254.80±45.98 | 239.65±47.04 | 247.43±50.72 |
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
与正常对照组相比,模型对照组大鼠饮水量显著升高(P<0.01);与模型对照组比较,样品1~8中剂量组均能显著降低大鼠给药第2、4、6、7周饮水量(P<0.05或P<0.01)。结果见表4、5。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.2对实验性2型糖尿病模型大鼠空腹血糖(FGB)的影响
与正常对照组比较,模型对照组大鼠给药期间空腹血糖显著升高(P<0.01),表明糖尿病模型造模成功;与模型对照组比较,样品1~8中剂量组能显著降低大鼠空腹血糖。结果见表6。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.3对实验性2型糖尿病模型大鼠糖耐量(GTT)的影响
与正常对照组相比,模型对照组大鼠口服葡萄糖后血糖显著升高(P<0.01),糖耐量血糖曲线下面积显著增加(P<0.01);与模型对照组比较,各给药组大鼠口服葡萄糖后血糖升高程度和糖耐量血糖曲线下面积有一定降低,但无统计学意义(P>0.05)。结果见表7。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.4对实验性2型糖尿病模型大鼠尿糖的影响
尿糖试纸半定量检测结果为浓度范围,等级分为阴性、0-100mg/dL、100-250mg/dL、250-500mg/dL、500-1000mg/dL、≥2000mg/dL 6个级别,检测结果按半定量计分分别计为0、1、2、3、4、5分。
与正常对照组比较,模型对照组大鼠尿糖显著升高(P<0.01)。与模型对照组比较,各给药组大鼠尿糖有一定降低趋势,但无统计学意义(P>0.05)。其中,样品1~3、样品6~8中剂量组大鼠尿糖的降低幅度高于样品4~5中剂量组大鼠尿糖的降低幅度。结果见表8。
项目 | 尿糖半定量计分 |
正常对照组 | 0.08±0.29 |
模型对照组 | 3.50±0.52<sup>△△</sup> |
样品1低剂量组 | 3.33±0.49 |
样品1中剂量组 | 3.33±0.49 |
样品1高剂量组 | 3.25±0.62 |
样品2中剂量组 | 3.17±0.43 |
样品3中剂量组 | 3.22±0.39 |
样品4中剂量组 | 3.42±0.45 |
样品5中剂量组 | 3.45±0.54 |
样品6中剂量组 | 3.23±0.43 |
样品7中剂量组 | 3.27±0.35 |
样品8中剂量组 | 3.14±0.31 |
消渴丸组 | 3.25±0.75 |
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.5对实验性2型糖尿病模型大鼠血脂的影响
与正常对照组比较,模型对照组大鼠总胆固醇和甘油三酯显著升高(P<0.05);与模型对照组比较,样品2~3、样品6~8中剂量组能显著降低大鼠甘油三酯(P<0.05),样品1也可以在一定程度上降低大鼠甘油三酯,但无统计学意义(P>0.05),样品8中剂量组可以显著降低大鼠总胆固醇(P<0.05)。结果见表9。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.6对实验性2型糖尿病模型大鼠胰岛素(INS)、胰岛素抵抗指数(IR)和胰岛素敏感指数(IAI)的影响。
与正常对照组比较,模型对照组大鼠血清胰岛素含量无明显变化(P>0.05),胰岛素抵抗指数显著升高(P<0.01),胰岛素敏感指数显著降低(P<0.01);与模型对照组比较,各给药组大鼠血清中胰岛素含量无明显变化(P>0.05),可在一定程度上降低胰岛素抵抗指数,升高胰岛素敏感指数;其中,样品2、样品6~8可显著降低胰岛素抵抗指数(P<0.05)。结果见表10。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.7对实验性2型糖尿病模型大鼠糖化血红蛋白(HAB1c)的影响
与正常对照组比较,模型对照组大鼠糖化血红蛋白显著升高(P<0.01);与模型对照组比较,样品2~8能显著降低大鼠糖化血红蛋白含量(P<0.05或P<0.01),样品1可以在一定程度上降低大鼠糖化血红蛋白含量,但无统计学意义(P>0.05)。结果见表11。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.8对实验性2型糖尿病大鼠胰岛素样生长因子(IGF-1)的影响
与正常对照组比较,模型对照组大鼠血清中胰岛素样生长因子显著降低(P<0.05);与模型对照组比较,各给药组能一定程度上升高大鼠血清中胰岛素样生长因子含量,但无统计学意义(P>0.05)。结果见表12。
项目 | 胰岛素样生长因子(IGF-1,ng/L) |
正常对照组 | 6.76±2.12 |
模型对照组 | 5.14±1.15<sup>△</sup> |
样品1低剂量组 | 6.19±1.73 |
样品1中剂量组 | 6.34±2.04 |
样品1高剂量组 | 6.63±2.24 |
样品2中剂量组 | 6.42±1.27 |
样品3中剂量组 | 6.51±1.31 |
样品4中剂量组 | 6.17±1.87 |
样品5中剂量组 | 6.25±2.10 |
样品6中剂量组 | 6.55±1.90 |
样品7中剂量组 | 6.52±1.78 |
样品8中剂量组 | 6.63±1.39 |
消渴丸组 | 6.64±1.59 |
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.9对实验性2型糖尿病模型大鼠血清中谷氨酸脱羟酶抗体(GADA)的影响
与正常对照组比较,模型对照组大鼠血清中谷氨酸脱羟酶抗体有升高趋势,但无统计学意义(P>0.05);与模型对照组比较,各给药组大鼠血清中谷氨酸脱羟酶抗体无明显变化(P>0.05)。结果见表13。
项目 | 谷氨酸脱羟酶抗体(GADA,nmol/L) |
正常对照组 | 5.91±0.34 |
模型对照组 | 6.24±0.48 |
样品1低剂量组 | 6.33±0.49 |
样品1中剂量组 | 6.18±0.49 |
样品1高剂量组 | 6.07±0.65 |
样品2中剂量组 | 6.03±0.43 |
样品3中剂量组 | 6.12±0.37 |
样品4中剂量组 | 6.20±0.43 |
样品5中剂量组 | 6.22±0.41 |
样品6中剂量组 | 6.19±0.37 |
样品7中剂量组 | 6.21±0.23 |
样品8中剂量组 | 6.01±0.28 |
消渴丸组 | 6.11±0.42 |
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.10对实验性2型糖尿病模型大鼠血清中C肽(C-p)的影响
与正常对照组比较,模型对照组大鼠血清中C肽显著升高(P<0.05);与模型对照组比较,样品1~8能显著降低大鼠血清中C肽含量(P<0.05或P<0.01)。结果见表14。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.11对实验性2型糖尿病模型大鼠血清中糖基化终末产物(AGEs)的影响
与正常对照组比较,模型对照组大鼠血清中糖基化终末产物有升高趋势,但无统计学意义(P>0.05);与模型对照组比较,各给药组大鼠血清中糖基化终末产物无明显变化(P>0.05)。结果见表15。
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
6.12对实验性2型糖尿病模型大鼠血清中转化生长因子β1(TGF-β1)的影响
与正常对照组比较,模型对照组大鼠血清中转化生长因子β1有升高趋势,但无统计学意义(P>0.05);与模型对照组比较,各给药组大鼠血清中转化生长因子β1无明显变化(P>0.05)。结果见表16。
项目 | 转化生长因子β1(TGF-β1,pg/mL) |
正常对照组 | 49.88±9.35 |
模型对照组 | 57.71±14.60 |
样品1低剂量组 | 50.53±11.12 |
样品1中剂量组 | 52.94±12.61 |
样品1高剂量组 | 55.65±13.83 |
样品2中剂量组 | 50.89±11.72 |
样品3中剂量组 | 51.36±12.65 |
样品4中剂量组 | 54.97±13.48 |
样品5中剂量组 | 55.27±15.43 |
样品6中剂量组 | 53.26±13.25 |
样品7中剂量组 | 52.51±12.93 |
样品8中剂量组 | 51.22±13.27 |
消渴丸组 | 55.58±14.85 |
注:模型组与正常对照组比较△P<0.05,△△P<0.01;给药组与模型对照组比较*P<0.05,**P<0.01。
由上述测试结果可知:与模型对照组相比,样品1~8能显著降低大鼠给药期间饮水量和空腹血糖,表明本发明所述中药组合物具有降低血糖和生津止渴的功效。此外,与模型对照组相比,样品2~3和样品6~8中剂量组均可明显降低大鼠血清中甘油三酯含量,样品1可以大幅降低大鼠血清中甘油三酯的含量,样品4~5也可以在一定程度上降低甘油三酯的含量;另外,样品8中剂量组还可以显著降低大鼠血清中总胆固醇含量;该结果表明,本发明所述中药组合物也具有良好的降血脂的作用。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,但并不脱离本发明技术方案的实质和范围。
Claims (10)
1.一种降血糖中药组合物,其特征在于,所述降血糖中药组合物包含如下重量份的成分:玉米须20~40份、葛根10~25份、黄精5~25份、桑叶5~20份、茯苓5~20份、山药5~10份和枸杞子5~10份。
2.如权利要求1所述的降血糖中药组合物,其特征在于,所述降血糖中药组合物包含如下重量份的成分:玉米须25~35份、葛根15~20份、黄精10~20份、桑叶8~15份、茯苓8~15份、山药5~10份和枸杞子5~10份。
3.如权利要求1或2所述的降血糖中药组合物,其特征在于,还含有乌梅1~10份。
4.如权利要求3所述的降血糖中药组合物,其特征在于,还含有百合1~10份。
5.一种由如权利要求1~4任一项所述降血糖中药组合物制成的中药浸膏,其特征在于,所述中药浸膏为浅棕色至黑褐色的膏状半流体,总黄酮含量≥0.25wt.%,粗多糖含量≥2.5wt.%。
6.一种如权利要求5所述的中药浸膏的制备方法,其特征在于,所述制备方法包括水提法、水提醇沉法、醇提法中的至少一种。
7.如权利要求6所述的中药浸膏的制备方法,其特征在于,所述制备方法为水提法,包括如下步骤:
(1)按中药材与水的重量比1:6~10添加水,微沸1~5h,过滤,得滤渣和滤液;
(2)将滤渣与水以1:5~9的重量比混合,重复上述步骤1~3次;
(3)将上述步骤获得的滤液混合,减压、浓缩,得到所述中药浸膏。
8.一种如权利要求1~4任一项所述的降血糖中药组合物在制备降血糖和/或降血脂和/或生津止渴的食品和药品领域中的应用。
9.一种药品,其特征在于,制备原料包含如权利要求1~4任一项所述的降血糖中药组合物和药物上可接受的辅料,所述药品的剂型为汤剂、散剂、丸剂、膏剂中的一种。
10.一种饮品,其特征在于,制备原料包含如权利要求1~4任一项所述的降血糖中药组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210285775.2A CN114569679A (zh) | 2022-03-22 | 2022-03-22 | 一种降血糖中药组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210285775.2A CN114569679A (zh) | 2022-03-22 | 2022-03-22 | 一种降血糖中药组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114569679A true CN114569679A (zh) | 2022-06-03 |
Family
ID=81775997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210285775.2A Pending CN114569679A (zh) | 2022-03-22 | 2022-03-22 | 一种降血糖中药组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114569679A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103859378A (zh) * | 2012-12-10 | 2014-06-18 | 天津红日药业股份有限公司 | 一种有助于降低血糖的养生保健食品配方及其制备方法 |
CN107441329A (zh) * | 2016-05-30 | 2017-12-08 | 王停 | 一种用于糖尿病兼干燥综合征调理的中药方剂 |
-
2022
- 2022-03-22 CN CN202210285775.2A patent/CN114569679A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103859378A (zh) * | 2012-12-10 | 2014-06-18 | 天津红日药业股份有限公司 | 一种有助于降低血糖的养生保健食品配方及其制备方法 |
CN107441329A (zh) * | 2016-05-30 | 2017-12-08 | 王停 | 一种用于糖尿病兼干燥综合征调理的中药方剂 |
Non-Patent Citations (1)
Title |
---|
紫和堂国医: "春季血糖易波动? 邓老支招助你稳血糖", 《HTTPS://MP.WEIXIN.QQ.COM/S/DQP5HF5GDO5OK7A3QEKCYG》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111840363B (zh) | 一种纳豆辅助降血糖保健组合物及其制备方法和用途 | |
CN115350242B (zh) | 一种糖脂代谢调节剂及其制备方法和应用 | |
CN106819833A (zh) | 一种降血糖调血脂的面条及其制备方法 | |
CN108578544A (zh) | 一种具有降糖作用的中药组合物及其制备方法与应用 | |
CN105816505A (zh) | 一种治疗糖尿病的中药复方制剂及其制备和应用 | |
CN113499366B (zh) | 一种具有同时降低血糖血脂功能的组合物及其制备方法 | |
CN101731401B (zh) | 一种玉竹速溶茶及其制备方法 | |
CN101167781A (zh) | 口服降血糖红薯叶单方中药及其制备方法 | |
CN114569679A (zh) | 一种降血糖中药组合物及其应用 | |
CN114209758A (zh) | 一种具有维持血糖健康水平的中药复方组合物及其制备方法与应用 | |
CN103705578A (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
CN1709415A (zh) | 石刁柏提取物及其制备方法 | |
CN1253733A (zh) | 护肝奶粉的配方及其生产工艺 | |
CN109316565B (zh) | 一种降血脂组合物及其制备方法和应用 | |
CN114533817A (zh) | 一种改善血糖和/或血脂的组合物及其应用 | |
CN103285113B (zh) | 一种预防和/或治疗糖尿病的药物组合物 | |
CN111888431A (zh) | 一种治疗糖尿病的组合物及其制备方法 | |
CN110801469A (zh) | 一种调节血糖的功能性食品及其制备方法 | |
CN109528957A (zh) | 一种具有护胃功效的中药复方制剂及其制备方法 | |
CN110623266A (zh) | 一种辅助降血糖保健食品及其制备方法 | |
CN110876717A (zh) | 一种可稳定血糖制品的制备方法 | |
CN116920061B (zh) | 一种治疗高血糖的中药组合物及其制备方法 | |
CN101584719B (zh) | 刺五加果提取物在制备治疗高血脂症药物中的应用 | |
CN107821538A (zh) | 一种降血糖的饼干及其制备方法 | |
CN114306544B (zh) | 一种降血糖组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220603 |